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Of all the infectious diseases first recognized in the 20th
century, AIDS has had not only the most profound effect on
human illness and death, it ended the developed world’s
complacency about infectious diseases. Caused by HIV, AIDS
is, as far as we know, always fatal, even with effective
therapy. Within the past 50 to 100 years, HIV went from being
maintained primarily, if not exclusively, in sooty mangabeys
(HIV-2) and chimpanzees (HIV-1) (1-3) to being the etiologic
agent of a worldwide pandemic. AIDS was not recognized as a
specific disease until 1980, and HIV was not identified as the
etiologic agent until 1983. Nevertheless, an estimated 16
million persons have died from AIDS worldwide with 50
million currently infected with HIV.
HIV exhibits considerable evolutionary potential and,
with drug-resistant bacteria, may have done more to enhance
widespread understanding of the importance of population
and evolutionary biology to human health and medicine than
any other example this past century. Although HIV was
initially susceptible to a variety of drugs, resistance
mutations have enabled the virus to skirt every drug in the
biotech arsenal. In part because of this capacity for rapid
evolution, developing an effective vaccine will be difficult.
In the study reported here, we used mathematical models
to consider the epidemiologic and evolutionary future of the
HIV/AIDS pandemic. We addressed four questions: 1) What
factors contribute to the spread and limiting the spread of
HIV/AIDS in human populations?  2) How long will it be
before resistance to HIV infections and/or their pathology
evolves in the human population? 3) Will evolution in the
HIV-infected population favor an increase or decrease in the
virulence of the virus? 4) What are the epidemiologic
consequences of life-prolonging treatment on the incidence of
HIV-infected persons and AIDS patients?
Age of Infection (AoI) Model
To consider the epidemiologic and evolutionary future of
HIV/AIDS, we developed a mathematical model for the
population dynamics of HIV/AIDS. Our model is based on those
typically employed by demographers and actuaries (see
reference 4 for our previous publication of it in a mathematical
context). Changes in the numbers of persons infected are treated
as a birth and death process; the “births” are new infections, and
“death” is removal of infected hosts from the population. The
course of an infection in an individual is characterized by (i) how
many new infections it generates at each time interval (week)
since that host was first infected (the equivalent of the birth
rate), and (ii) the weekly likelihood of the removal of a host from
the population (the death rate). By “age,” we mean the “age of
infection” (AoI)—the time in weeks since that host was first
infected. Within this framework, an HIV infection has a life cycle
different from that of most viral and other microparasitic
infections, because the onset of the disease, AIDS, occurs long
after the person is infected with HIV and the microparasite has
started to proliferate. Although the passage through time and
progression to disease is continuous, for tradition as well as
convenience it is useful to characterize an HIV infection as
having four distinct stages, which are described and given
parameters in Table 1.
In the numerical (computer) simulation used here, infected
persons pass through the HIV/AIDS gauntlet on a weekly basis.
Each week throughout stage i of the infection they cause Ri/Li
new infections (R = new infections; L = duration in weeks); these
newly infected hosts then enter the gauntlet. (Note that the rate
of transmission during a stage thus depends both on Ri and Li,
not just on Ri.)  Each infected host continues to progress through
the different stages and transmit the virus until the final week of
the third stage, L3, when the infected host dies. For more details
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about the model see (4). Copies of the FORTRAN 77 program
used for the numerical results presented here can be obtained
from Bruce Levin.
HIV Dynamics
When an infectious disease is first introduced into a
population, it has the greatest opportunity to spread because all
hosts are susceptible. Thus, if we introduce a single infected
person into a wholly susceptible population, the maximum
opportunity exists for producing secondary infections, the
number of which is traditionally designated as R0 (1). Although
R0 is a measure of the potential of a disease to spread in a
population, it not a measure of the rate at which that disease will
spread. One way to measure the rate at which a disease spreads
in a wholly susceptible host population is that used by
demographers to represent the geometric expansion rate of
populations, the intrinsic rate of increase,  r . N persons at time
0 become Nert persons at time t, where e is the base of the natural
logarithm  (if  N were an amount of money, r would be the
compound interest rate; in this case, r is the intrinsic rate of
increase in the number of infected persons). With age structure
in the model, a certain “settling out” period occurs in which the
ratios of numbers of infections at different stages oscillate. As
these oscillations decay, r approaches its steady state value,
which can be calculated from the rate of change in any of the age
categories of the AoI distribution.
The long duration of infection is important in
understanding the intrinsic rate of increase of HIV and its
dissemination through a population. During the epidemic
phase of the disease, when there are many susceptible hosts
and the number of new infections is increasing geometrically,
the contribution of transmissions occurring at later stages of
the infection to the spread of the virus is severely discounted
(4, 5). Thus, new infections transmitted by recently infected
persons, in stage 1, contribute much more to the spread of HIV
than infections from persons in stage 3 (12 years later).
To illustrate this principle, let us use the AoI distribution
employed in our original study (4) and assume that all
transmission of the virus is confined to just one of the four
stages. A rate of increase of HIV of 0.50 per year (HIV
infections doubling every 1.4 years) would require (a) 1.1
secondary infections if transmission occurred solely in stage 1
(between weeks 6 and 12 after the host is infected in our
example); (b) 5.2 secondary infections if transmission
occurred solely during the asymptomatic period (an average of
10 years in our example); and (c) 72 secondary infections if
transmission occurred solely during the period after the onset
of AIDS (at an AoI between 10 and 12 years in our examples.
In perhaps more familiar terms, we can assume a direct
analogy between these results and the concept of compound
interest; models for the spread of disease in a population are
formally analogous to economic models for the growth of
money in an account. An interest rate of 1% per day,
compounded daily, yields an annual rate of 3,800%. In a
similar manner, new infections produced during stage 1
compound themselves many times within the 10-year period
during the advance to AIDS. One implication of this result is
that when HIV first enters a naïve population, if transmission
occurs within the first month of infection, this early
transmission will drive the epidemic. Using a different model
and a closer tie to real data, Jacquez, Koopman and colleagues
made a similar argument that early transmission is
important in driving the epidemic (6, 7). This conclusion has
a number of implications, the most immediately practical of
which is that public health and education procedures to
control the epidemic will fail if they are based on using
serologic test results to identify infected persons (6). Infected
persons may well have transmitted the virus before they
seroconverted.
Factors Limiting the Rate of Spread of HIV/AIDS
What limits the rate at which HIV spreads through a
population?  Although at least 50 million persons are infected
with HIV, the human population (more than 6 billion persons)
consists almost entirely of uninfected persons, and the global
rate of increase in new HIV infections does not appear to have
abated. However, unlike the case with influenza and measles,
considerable geographic and cultural variation exists in the
epidemiology of HIV/AIDS. In effect, the HIV pandemic has
been largely restricted to subpopulations—risk groups within
which the likelihood of infection is substantially greater than
that in the population at large, e.g., gay men, injection drug
users, and sex workers, their patrons, and their spouses (or
other sex partners).
It seems reasonable as well as hopeful to expect that the
rate of increase in new HIV infections will decline in a number
of different populations. What processes can account for these
declines in the incidence of new HIV infections and reductions
in the rate of spread of this virus?   Do they reflect the efficacy
of public health measures and education programs leading to
more prudent sexual and needle use behavior? Has
chemotherapy reduced the transmissibility of the virus?  Is
evolution making these viruses less transmissible or humans
less susceptible to HIV infections or both?  Although it would
be difficult to reject the possibility of these different factors
contributing to reductions in the rate at which new HIV
infections are increasing, it may well be that the dominant
reason for observed declines in the rate of spread of this
retrovirus lies in the progression (and confinement) of the
epidemic in particular subpopulations (risk groups). The
Table 1. Stages in the age of infection (AoI) model used in this investigation
Duration New Death
Stage Characteristics (weeks) infectionsa   rate
0 Establishment: virus enters and colonizes host L0 00
1 Primary infection: virus proliferates to high densities; the host L1 R1 0
  seroconverts, which causes an abrupt decline in the titer of circulating
  virus
2 Asymptomatic:  circulating virus remains at low levels, and disease L2 R2 0
   symptoms are absent
3 AIDS L3 R3 100% at end
aTotal number of new infections produced by persons in this stage.507 Vol. 7, No. 3 Supplement, June 2001 Emerging Infectious Diseases
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reductions in the spread of HIV in these subpopulations could
be due to the saturation of the pool of susceptible hosts in
these groups rather than to successful intervention or
behavioral changes (see 7).
To illustrate the effect of the saturation of susceptible
hosts in risk groups, we can consider a single AoI distribution
in which the duration of the four different stages (L0-L3) are,
respectively,4, 6, 520, and 104 weeks. During each of the
latter three stages, in a wholly susceptible population, each
infected person produces one secondary infection, R01 = R02 =
R03 =1.
As the infection spreads, fewer susceptible persons exist,
and the number of secondary infections caused by each infected
individual will be somewhat less than the maximum rate. We
assume that the realized rates of transmission of HIV during
each stage of the infection (R1, R2, and R3) decline at a rate
proportional to their respective maximum rates and the fraction
of the population that is susceptible to the infection. For
example, at an given time, t, R1(t) =  R01S(t) /N, where S(t) is the
number of susceptible hosts at time t and N is the total number
of persons in that population, which is held constant. Since we
are assuming that AIDS is the only cause of death, to maintain
N, a susceptible host replaces each person that dies of AIDS.
Figure 1A shows how the densities of susceptible hosts,
HIV-positive persons without AIDS, and persons with AIDS
change over the course of time in a population with an initial
number of 104 susceptible hosts and two HIV-positive persons
at the earliest age of the infection (week 1). The virus rapidly
spreads through the host population who exhibit no sign of
AIDS for the first 10 years. By the time the first AIDS cases
are recognized, more than half of the original population of
10,000 hosts are infected with the virus. Because of the
relative dearth of susceptible hosts, the rate of spread of HIV
to new hosts has already declined. Eventually, equilibrium is
achieved and the infection maintains a steady state. In this
endemic phase, the densities of susceptible hosts, HIV-
positive hosts not manifesting the symptoms of AIDS, and
AIDS patients level off. With these parameters, this endemic
phase is reached in about 30 years.
A historical interpretation of this result is that by the
time HIV infection was recognized as a specific disease in the
gay male populations of San Francisco, Los Angeles, and New
York in the early 1980s, a substantial proportion of persons in
those subpopulations, were already infected with the virus
(6). Moreover, by that time, HIV/AIDS may have already been
approaching its endemic phase in these risk groups. The rate
at which endemic phase is approached as well as the
frequency of HIV-positive persons and AIDS patients within a
subpopulation depends on the absolute rate of transmission.
This is illustrated in Figure 1B. The parameters used for
generating this figure are identical to those in Figure 1A,
except for the maximum rates of increase, which have been
reduced by a factor of two, R01 = R02 = R03 = 0.50.
As a consequence of this lower rate of transmission, the
endemic phase is not reached for more than 100 years, and the
proportion of the population that is HIV-positive and has
AIDS is markedly reduced.
The simple explanation of these results is that an
epidemic cannot continue forever because the number of
uninfected hosts eventually declines, which stops the
expansion of infections. At equilibrium, the fraction of
infected versus uninfected hosts depends on various
parameters that are subsumed in the R0is of our model. Using
condoms, reducing the numbers of sexual partners, providing
sterile needles for injection drug users, and any other factor
that reduces the likelihood of transmission of the virus would
further reduce the fraction of the subpopulation infected with
HIV. Also affecting the rate of spread of the disease would be
the rate at which susceptible hosts enter a risk group. We
hope this rate can be reduced by education.
Evolution
Evolution in the human population could ultimately
reduce the likelihood of becoming infected with a
microparasite or of acquiring the disease if infected. Such
changes in the host population could also impact the
epidemiology and evolution of that microparasite. In this
section, we describe simple models for human evolution in
response to HIV and evolution of HIV’s virulence in HIV-
infected persons. We argue that it will take thousands of years
before evolution in the human population substantially
increases the fraction of persons resistant to HIV/AIDS.
Evolution in the HIV-infected population at large, on the
other hand, can proceed at an extremely high rate. On
epidemiologic grounds, it is unlikely that evolution in this
Figure 1. The spread of HIV/AIDS in a steady population of 10,000.
In this figure, HIV-positive includes all persons infected with this
virus, but not manifesting the symptoms of AIDS. In this
simulation, the four stages of the infection, 0, 1, 2, and 3 are,
respectively, 4, 6, 520, and 104 weeks (L0 = 4, L1 = 6, L2 = 520, and
L3 = 104). We assume that HIV is not transmitted during the first
4 weeks, stage 0. A) In a wholly susceptible host population during
each stage 1, 2, and 3, infected host will be responsible for one
secondary infection, R01 = 0, R01 = R02 = R03 = 1.0. B) In a wholly
susceptible host population during stages 1, 2, and 3, each infected
host will be responsible for one secondary infection, R01 = 0, R01 =
R02 = R03 = 0.50.508 Emerging Infectious Diseases Vol. 7, No. 3 Supplement, June 2001
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virus will make it more virulent (reduce the time between
infection and the onset of AIDS) and may, in fact, favor
reductions in virulence.
Host Evolution
As long as an infectious disease causes some persons to die
before or during reproductive years or to otherwise reduce the
number of children they produce, natural selection will favor
persons who are less susceptible to the infection and its
deleterious effects. In the case of HIV, some evidence exists for
inherited variation in the likelihood of HIV infection and in the
rate of progression to AIDS among HIV-infected persons (8, 9).
On the other hand, even under optimal conditions for rapid
evolution—disease resistance is complete and determined by the
genotype at a single locus—if the resistance gene is initially rare,
it will take millennia before a substantial fraction of the
population is of the resistant genotype.
This slowness of human evolution is illustrated in Table 2,
in which we calculate the number of years required for a gene
that confers a 10% advantage on a favored gene to reach a
frequency of 0.50 for different initial frequencies of that gene and
different modes of inheritance. For this calculation, we use the
standard population genetics model for selection in a diploid
population (10) and assume an average generation time of 20
years. In the case of infectious disease, the intensity of selection
depends on the incidence of the disease as well as its effect on the
fitness of infected hosts, so a 10% advantage for resistance could
represent 20% of the population infected and a 50% loss of
fecundity per infection, and so on. Thus, even if the genetic
conditions for selection for resistance to AIDS were optimal, and
the fertility of infected persons was substantially reduced, the
intensity of selection for the resistant genotype would be no
greater than the frequency of the infection in the population.
Although in some populations the frequency of HIV infections is
tragically and appallingly high, in the human population at
large that frequency remains substantially less than 1%.
Moreover, HIV-infected persons do produce viable uninfected
children. The implications of this are straightforward if not
optimistic: we cannot count on evolution in our population to
save us from the AIDS epidemic, at least not in our lifetimes or
that of many generations to come. On the other hand, in some
areas, sub-Saharan Africa in particular, the incidence of the
disease in the heterosexual population is so high that the
intensity of selection for resistance would be considerably
greater than 1%. If genes for resistance to HIV were present in
the African population, resistance may in fact become common in
sub-Saharan Africa more rapidly than in the human population
at large. In any event, many persons will die of AIDS during the
evolution process (11).
HIV Evolution of Virulence
Although human evolution is slow by our standards, HIV
evolution will likely be rapid. Indeed, this retrovirus has already
demonstrated its capacity for rapid evolution on several fronts,
for example, the development of drug resistance and the ability
to avoid the immune system. There is every reason to expect that
HIV could evolve to a form with a different level of virulence in
human hosts. Not so clear, however, is whether natural selection
will favor changes in the virulence of this retrovirus or, if so, in
what the direction that change would be. To predict the direction
of natural selection on the virulence of HIV, we have to know the
relationship between the virulence of this virus and its capacity
for infectious transmission. Will HIV variants that engender a
higher rate of progression to AIDS also be more transmissible
and thus have an advantage over HIV variants that engender a
lower rate of progression? Although a positive relationship
between the transmissibility of HIV and its virulence has been
proposed (12), no evidence supports this interpretation. Indeed,
theoretical studies of the mechanisms of HIV virulence and
experimental studies with simian retrovirus SIVSM, which is
almost identical to HIV-2, have found no evidence of a
relationship between progression to AIDS and viral load or of a
positive relationship between the transmissibility and virulence
of HIV (13-19; M. Feinberg and S. Staprans, pers. comm.).
Models of the epidemiology of HIV/AIDS can be used to elucidate
how natural selection will operate on the virulence of HIV under
different assumptions about the rate of progression to AIDS and
the transmissibility of the virus.
Towards this end, we used our AoI model to explore how
natural selection will operate in populations of humans
infected with HIV who have different rates of progression to
AIDS as measured by the length of the asymptomatic period.
We made the simple and plausible assumption that
transmission rates are constant within each stage of the
infection and across different viruses, but that the total
number of transmissions over the course of the infection
varies only with the length of the stage of infection, Li. This
assumption constitutes a relationship between the virulence
of this virus and its capacity for infectious transmission in a
direction opposite from that assumed in (12), in that an
earlier onset of AIDS is associated with fewer total
transmissions from an infection.
Contrary to what may be anticipated from equilibrium
considerations, with this model, a strain with a lower net
yield of secondary infections can, under some conditions, have
a selective advantage over a more productive strain. More
specifically, if virulence is associated with a greater rate of
transmission early in the infection, during the epidemic
phase of the disease it could be favored, even if the overall
transmission rate is reduced due to the earlier death of the
infected host. This, too, is a manifestation of the advantages of
early and discounting late transmission. On the other hand,
as the disease approaches the endemic phase, the total
amount of transmission over the term of the infection becomes
increasingly important. During that stage, more virulent
strains will be at a disadvantage unless they also have a
higher overall rate of transmission.
To illustrate these points about the relationship between
the epidemiology of the disease and the direction of selection
for and against virulence, we used the AoI model to consider
two distributions based on different lengths of time in the
asymptomatic phase. The AoI distribution for the more
Table 2. Years before the frequency of a gene that confers a 10%
advantagea to reach 0.50
Initial Mode of inheritance
frequency No dominance Dominant Recessive
0.01 1,838 1,054 41,038
0.001 2,763 1,964 401,963
0.0001 3,684 2,884 4,002,884
aWe are assuming that favored genotype has a 10% advantage over the other
genotypes; in the no dominance case, the relative fitness of the heterozygote is
intermediate between that of the two homozygotes. With a 1% selective advantage,
it would take 10 times as long for the gene to reach a frequency of 50%.509 Vol. 7, No. 3 Supplement, June 2001 Emerging Infectious Diseases
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virulent strain is characterized by parameters denoted with
an asterisk (*) and that of the less virulent strain is the same
as in Figure 1 (the asymptomatic period lasts 10 years). For
the more virulent strain, the asymptomatic phase is 5 years
(L2 = 10, L2* = 5). The weekly rate of transmission within each
stage is the same for both variants, but the more virulant
variant experiences a shorter infection life span and thus
produces proportionally fewer secondary infections, than the
less virulent strain (R02 = 1.0, R02* = 0.5).
Figure 2A plots the changes in the total density of
susceptible persons, HIV-positive persons, and persons with
AIDS and the relative frequency of the more virulent virus.
The frequency of the more virulent strain increases initially
due to its early progression to AIDS and the consequent
higher weekly rate of transmission during that stage. As the
epidemic wanes and the endemic phase approaches, the
frequency of this more virulent strain declines because it
produces fewer secondary infections over the lifetime of the
infection. Thus in this case, selection temporarily favors an
increase in the virulence of HIV, but over the long term,
reductions in the virulence of HIV will be favored.
If, for physiologic reasons, a faster progression to AIDS
(stage 3) is associated with a higher absolute rate of
transmission during earlier stages, during the epidemic
phase of the disease, the rate of increase of the more virulent
strain would be greater.  Also greater would be the frequency
before onset of the endemic phase and the intensity of
selection against virulence (compare Figures 2A and 2B).
Stated another way, even if there were a direct association
between transmission and virulence during the early stage of
the infection, virulence would eventually be selected against
as the virus became endemic, provided that the total number
of transmissions is lower for the more virulent strain.
Nonetheless, one should interpret these results cautious-
ly because the evidence that no relationship exists between
the virulence of HIV and its transmissibility remains largely
circumstantial, albeit more compelling than that for a
positive relationship. Until the results of studies addressing
this issue become unequivocal, we cannot rule on the
plausibility of the different scenarios for evolution of
increasing or decreasing virulence of this retrovirus.
Epidemiologic Consequences of Treatment
It may be some time before we have vaccines that are
effective in preventing HIV infections. On the other hand,
multidrug chemotherapy substantially prolongs the life of
HIV-infected persons. For those who can afford this relatively
expensive therapy or otherwise have access to these drugs,
multidrug chemotherapy has literally been a lifesaver. From
an epidemiologic perspective, however, is there a downside to
this therapy?
On first consideration, it seems obvious that if treated
HIV-infected persons survive longer and continue to transmit
the virus at the same rates as they would have without
chemotherapy, the virus will spread more rapidly than it
would in the absence of treatment. This “perverse” effect of
therapy was in fact explained nearly 10 years ago in a
theoretical study by Anderson, Gupta and May (20). That
research was based on a compartment model that was more
specific about the mode of transmission than is our AoI model,
but it did not take into account either the AoI distribution or
reductions in transmission rates due to the limitation of
susceptible hosts. They concluded “that in communities
where the transmission rate of HIV is low, but sufficient for
long-term persistence (R0 not much greater than unity),
treatment that lengthens the infectious period is likely to be
able to increase the overall transmission rate to more than
counterbalance the greater longevity of infected persons who
are treated.”  Anderson and his collaborators also concluded
that when transmission rates are already high, community-
wide treatment would benefit both the individual and the
community.
We used the AoI model to explore this question of the effect
of treatment on the epidemiology of AIDS. If we assume that
treatment extends the survival time of AIDS patients and has no
Figure 2. Evolution of HIV virulence in a steady state host population
of 10,000. There are two HIV strains in these simulations. For one,
the asymptomatic periods is 520 weeks and, in the more virulent
population (*), it is 260 weeks. The duration of stages 0,1, and 3 is
identical for both populations and the same as those in Figure 1. A)
The weekly rates of transmission of the virus are identical in both
populations, so that during the asymptomatic period in a wholly
susceptible host population, the more virulent strain of HIV is
responsible for 0.5 rather than 1 secondary infection, R02* = 0.5, while
R01 = 1.0. The remaining R0s of these two populations are identical to
those in Figure 1. B) Early transmission in the more virulent strain
is greater than that in the less virulent, R01* = 1.05, while R01 = 1.0
secondary infections. The weekly rates of transmission of are same for
rest of the stages, R00
* = R00 =0,  R02
* = 0.5, R02 = 1, and R03
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effect on the rate transmission, then our results are the same as
those of Anderson and colleagues (20). Treatment can increase
the rate at which persons become HIV-positive and later acquire
AIDS. On the other hand, there is every reason to expect that
anti-HIV chemotherapy will markedly reduce the density of HIV
in serum and strong evidence that transmission rates are
directly proportional to the density of HIV in serum. Indeed, the
results of an impressive recent study of HIV transmission by
Quinn and colleagues (21) suggest that transmission will not
occur at all when the viral titers are <1,500 copies/ml. With
successful multidrug HIV therapy, viral titers of that level and
lower can be expected and sustained for some time during the
course of treatment.
Thus, the question of concern now is—what are the effects of
reduced transmission of HIV from treated patients on the
epidemiology of HIV/AIDS? To address this question, we used
our AoI model to explore the effects of chemotherapy on the
fraction of HIV-positive persons (non-AIDS) and persons with
AIDS in treated and untreated groups during the epidemic and
endemic phases of the disease. We considered a situation in
which the overall rate of transmission in untreated hosts is
relatively low, R00 = 0, R01 = R02 = R03 = 0.5 when the negative
epidemiologic consequences of treatment are anticipated to be
most profound (20). We assumed that treatment would extend
the time before a person manifests the symptoms of an HIV
infection, AIDS, by a factor of three, from 2 to 6 years. Here,
parameters for a treated host will be denoted with *; L3 = 104
weeks, L3* = 312 weeks. In one case,  we assumed that treatment
has no effect on the total number of viruses transmitted by a
person with AIDS, but that it reduces the weekly rate of
transmission by a factor of three. That is, in the course of the
threefold increase in survival time, treated persons would be
responsible for as many secondary infections as untreated AIDS
patients (R03 = R03
*= 0.5). In the second case,we assumed that
treatment reduces the overall transmission by persons with
AIDS by a factor of two (R03 = 0.5, R03
*= 0.25).
To illustrate the effect of treatment in these situations, we
compare what happens to the incidence of HIV and AIDS in a
population in which AIDS patients are treated with a
corresponding population in which they are not.  If treatment has
no effect on the overall rate of transmission, extending the life of
AIDS patients will have virtually no effect on the fraction of the
population infected with HIV (Figure 3A). While the infection is
in the endemic phase, treatment increases the fraction of the
population with AIDS by a factor of three, primarily by
increasing the lifespan of AIDS patients by that amount. If, as
seems reasonable to expect, chemotherapy actually reduces the
overall transmission by persons with AIDS (Figure 3B), its
epidemiologic effects will be positive. The incidence of HIV
infections will be markedly reduced, and not until later in the
endemic phase will the proportion of the population with AIDS
increase, and that will be due largely to extending the lifespan of
AIDS patients.
Conclusions, Caveats, and Recommendations
The results of this theoretical study and others have
generated the following hypotheses, predictions, and specula-
tions about the epidemiologic and evolutionary future of HIV/
AIDS. 1) The AIDS epidemic has been driven primarily by
transmission of the virus early in the course of infection. 2)
Declines and leveling off in the incidence of new HIV infections in
subpopulations (risk groups) could be largely due to a dearth of
susceptible hosts in (or entering) the subpopulation rather than
to the efficacy of public heath measures, education, and
chemotherapy or to the evolution of the virus. 3) Although AIDS-
mediated selection in the human population will eventually
increase the overall level of resistance to HIV infection or reduce
the rate (and maybe even the likelihood) of progression to AIDS,
it will take millennia before human evolution alone will
significantly increase our resistance to HIV/AIDS. 4)
Epidemiologic considerations provide no reason to anticipate
that evolution will increase the virulence of HIV. 5) In
populations in which HIV is relatively rare, treatment that
simultaneously extends the lifespan of persons with HIV, and
also reduces the rate of transmission of the virus, can lead to
substantial declines in the number of HIV-infected persons in
the general population.
We have evaluated the possible consequences of
different properties of HIV transmission and evolution.
However, despite all that has been learned about HIV/
AIDS, existing knowledge about the biology and
epidemiology of this retrovirus is still too rudimentary to
employ empirical estimates of these parameters. Thus, it is
not yet possible to make robust, quantitative predictions
about (and explanations for) the epidemic and endemic
behavior of HIV or the evolution of its virulence. Towards
these desired ends, however, we believe that the AoI model
Figure 3. The effect of treatment on the relative frequency of HIV-
positive persons (non-AIDS), and persons with AIDS in a steady state
population of 10,000. In the untreated population, the duration of
AIDS is 2 years, 104 weeks, before the patient dies, whereas in the
treated population (*), it is 6 years, 312 weeks. The length of the other
stages are identical to those in Figure 1. A) No effect of treatment on
the overall transmission of HIV by AIDS patients, but a 1/3 reduction
in the weekly rate of transmission. R00 = R00
*
 = 0, R01 = R01* = R02 = R02*
= 0.5, R03 = 0.5, R03* = 0.5. B) Treatment reduces the overall rate of
transmission by AIDS patients by a factor of two. R00 = R00
*
 = 0, R01 =
R01* = R02=R02* = 0.5, R03 = 0.25, R03* = 0.25511 Vol. 7, No. 3 Supplement, June 2001 Emerging Infectious Diseases
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considered here and other mathematical models of the
epidemiology of HIV serve the important role of revealing
which properties of infections with this retrovirus and
transmission are critical to understanding how it spreads,
how to control that spread, and what to look for to predict
the direction of evolution of its virulence.
Even without precise estimates of the values of these
parameters, theoretical studies of the epidemiology of HIV
make a number of unequivocal predictions. One is that early
transmission will dominate the spread of HIV in naive
populations. Another is that in populations in which HIV is
relatively rare, treatment that does not reduce transmission
rates can exacerbate the epidemic, and treatment that does
reduce transmission can benefit the population as well as the
patient. A broader, more definitive, and more quantitatively
precise set of predictions about the epidemiologic and
evolutionary future of HIV/AIDS will require data addressing
the following questions. What are the rates of transmission of
HIV during different stages of the infection?   What effect does
multidrug therapy have on the rate at which this virus is
transmitted?  Also critical to predicting the future HIV/AIDS
is an objective and quantitative assessment of the
demographic, behavioral, medical, and other reasons for
changes in the incidence of HIV infections in different
subpopulations. Are the declines in the rate of new HIV
infections due to the efficacy of public health and education
measures or, as suggested here, are they due to the saturation
of the susceptible hosts in that risk group? Finally, to formally
address the question of how HIV evolution will affect
virulence of this retrovirus, we must know how much of the
variation in the rate of progression to AIDS can be attributed
to variation in the HIV-infected population.
Such data are not easy to obtain. Indeed, the potential
importance of early HIV transmission (before seroconversion)
was identified nearly a decade ago, yet little data have been
collected on the magnitude of early transmission or on the
amount of transmission occurring during other stages of the
infection. From the narrow perspective of funding and
careers, embarking on a research program directed at the
acquisition of such data may be unwise. Gathering those
kinds of data certainly lacks the romance and appeal of
vaccine and drug development or the yield of generating more
data on sequence variation. Nevertheless, without these
transmission data, predictions about the epidemiologic and
evolutionary future of HIV/AIDS will have to be relegated
entirely (and, we believe, unsatisfactorily) to mathematical
modeling.
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